Viking Therapeutics, Inc. (0VQA.L)

USD 39.07

(-17.95%)

Total Liabilities Summary of Viking Therapeutics, Inc.

  • Viking Therapeutics, Inc.'s latest annual total liabilities in 2023 was 20.07 Million USD , down -13.51% from previous year.
  • Viking Therapeutics, Inc.'s latest quarterly total liabilities in 2024 Q2 was 25.85 Million USD , down -23.1% from previous quarter.
  • Viking Therapeutics, Inc. reported annual total liabilities of 23.2 Million USD in 2022, up 164.38% from previous year.
  • Viking Therapeutics, Inc. reported annual total liabilities of 8.77 Million USD in 2021, down -27.8% from previous year.
  • Viking Therapeutics, Inc. reported quarterly total liabilities of 25.85 Million USD for 2024 Q2, down -23.1% from previous quarter.
  • Viking Therapeutics, Inc. reported quarterly total liabilities of 33.62 Million USD for 2024 Q1, up 67.54% from previous quarter.

Annual Total Liabilities Chart of Viking Therapeutics, Inc. (2023 - 2012)

Historical Annual Total Liabilities of Viking Therapeutics, Inc. (2023 - 2012)

Year Total Liabilities Total Liabilities Growth
2023 20.07 Million USD -13.51%
2022 23.2 Million USD 164.38%
2021 8.77 Million USD -27.8%
2020 12.15 Million USD 70.35%
2019 7.13 Million USD 56.44%
2018 4.56 Million USD -47.3%
2017 8.65 Million USD 33.32%
2016 6.49 Million USD -3.3%
2015 6.71 Million USD -73.33%
2014 25.17 Million USD 5740.32%
2013 430.99 Thousand USD 308.86%
2012 105.41 Thousand USD 0.0%

Peer Total Liabilities Comparison of Viking Therapeutics, Inc.

Name Total Liabilities Total Liabilities Difference
Editas Medicine, Inc. 150.05 Million USD 86.624%
Dynavax Technologies Corporation 375.02 Million USD 94.648%
Supernus Pharmaceuticals, Inc. 487.46 Million USD 95.883%
Perrigo Company plc 6.04 Billion USD 99.668%
Illumina, Inc. 4.36 Billion USD 99.54%
Thermo Fisher Scientific Inc. 51.88 Billion USD 99.961%
Iovance Biotherapeutics, Inc. 195.73 Million USD 89.746%
Walgreens Boots Alliance, Inc. 68.85 Billion USD 99.971%
IQVIA Holdings Inc. 20.56 Billion USD 99.902%
Heron Therapeutics, Inc. 256.47 Million USD 92.174%
Regeneron Pharmaceuticals, Inc. 7.1 Billion USD 99.718%
Unity Biotechnology, Inc. 37.29 Million USD 46.179%
Waters Corporation 3.47 Billion USD 99.423%
Biogen Inc. 12.04 Billion USD 99.833%
Sangamo Therapeutics, Inc. 82.43 Million USD 75.652%
Evolus, Inc. 209.68 Million USD 90.428%
Adicet Bio, Inc. 37.12 Million USD 45.929%
Cara Therapeutics, Inc. 68.75 Million USD 70.81%
bluebird bio, Inc. 424.62 Million USD 95.273%
Esperion Therapeutics, Inc. 660.79 Million USD 96.963%
FibroGen, Inc. 585.72 Million USD 96.573%
Agilent Technologies, Inc. 4.91 Billion USD 99.592%
Corbus Pharmaceuticals Holdings, Inc. 35.17 Million USD 42.943%
Homology Medicines, Inc. 118.53 Million USD 83.067%
Geron Corporation 146.12 Million USD 86.265%
Alnylam Pharmaceuticals, Inc. 4.05 Billion USD 99.504%
Amicus Therapeutics, Inc. 617.7 Million USD 96.751%
Myriad Genetics, Inc. 312.9 Million USD 93.585%
Intellia Therapeutics, Inc. 250.8 Million USD 91.997%
Zoetis Inc. 9.29 Billion USD 99.784%
Abeona Therapeutics Inc. 49.17 Million USD 59.185%
Mettler-Toledo International Inc. 3.5 Billion USD 99.427%
BioMarin Pharmaceutical Inc. 1.89 Billion USD 98.938%
Vertex Pharmaceuticals Incorporated 5.14 Billion USD 99.61%
Kala Pharmaceuticals, Inc. 48.44 Million USD 58.57%
Ionis Pharmaceuticals, Inc. 2.6 Billion USD 99.229%
Atara Biotherapeutics, Inc. 264.73 Million USD 92.418%
Verastem, Inc. 71.18 Million USD 71.804%
Nektar Therapeutics 267.04 Million USD 92.484%
Axsome Therapeutics, Inc. 397.25 Million USD 94.948%
Aclaris Therapeutics, Inc. 40.22 Million USD 50.104%
Sarepta Therapeutics, Inc. 2.4 Billion USD 99.166%
OPKO Health, Inc. 622.47 Million USD 96.776%
Exelixis, Inc. 678.44 Million USD 97.042%
Neurocrine Biosciences, Inc. 1.01 Billion USD 98.031%
Corcept Therapeutics Incorporated 114.81 Million USD 82.518%
Anavex Life Sciences Corp. 12.53 Million USD -60.132%
uniQure N.V. 624.01 Million USD 96.784%
Imunon, Inc. 8.53 Million USD -135.287%
Blueprint Medicines Corporation 918.64 Million USD 97.815%
Insmed Incorporated 1.66 Billion USD 98.792%
Halozyme Therapeutics, Inc. 1.64 Billion USD 98.783%
Agios Pharmaceuticals, Inc. 126.09 Million USD 84.083%
TG Therapeutics, Inc. 169.08 Million USD 88.13%
Incyte Corporation 1.59 Billion USD 98.739%
Emergent BioSolutions Inc. 1.18 Billion USD 98.307%